BidaskClub Downgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) to Hold

Dicerna Pharmaceuticals (NASDAQ:DRNA) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Tuesday, January 9th.

A number of other research firms also recently weighed in on DRNA. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Dicerna Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $6.81.

Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at $8.42 on Tuesday. Dicerna Pharmaceuticals has a 1 year low of $2.42 and a 1 year high of $10.24. The company has a market cap of $434.82, a PE ratio of -2.45 and a beta of 2.85.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The firm had revenue of $0.47 million for the quarter. During the same quarter last year, the firm earned ($0.68) EPS. The firm’s quarterly revenue was up 192.6% on a year-over-year basis. equities analysts predict that Dicerna Pharmaceuticals will post -2.93 EPS for the current fiscal year.

In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Monday, December 18th. The stock was acquired at an average price of $7.00 per share, with a total value of $1,995,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 29.41% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its holdings in Dicerna Pharmaceuticals by 6.1% during the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares during the last quarter. Birchview Capital LP boosted its holdings in shares of Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 25,000 shares during the last quarter. Deschutes Portfolio Strategy LLC purchased a new position in shares of Dicerna Pharmaceuticals in the 3rd quarter worth about $575,000. Vanguard Group Inc. boosted its holdings in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after buying an additional 14,517 shares during the last quarter. Finally, Palo Alto Investors LLC boosted its holdings in shares of Dicerna Pharmaceuticals by 4.0% in the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after buying an additional 19,394 shares during the last quarter. 21.93% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first published by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/dicerna-pharmaceuticals-drna-downgraded-by-bidaskclub-to-hold/1820059.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.